{"url_path":"/sec/atyr/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1339970/0001339970-26-000033-index.html","accession_number":"0001339970-26-000033","cik":"0001339970","ticker":"ATYR","issuer_name":"aTYR PHARMA INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1339970/0001339970-26-000033-index.html","primary_entity_key":"0001339970","primary_entity_name":"aTYR PHARMA INC"},"word_count":520,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nIndex to Exhibits\n\n \n\n \n\nIncorporated by Reference\n\n \n\nExhibit\n\nNumber\n\nExhibit Title\n\nForm\n\nFile No.\n\nExhibit\n\nFiling Date\n\n3.1\n\n[Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1339970/000095017022024724/life-ex3_1.htm)\n\n10-Q\n\n001-37378\n\n3.1\n\nNovember 14, 2022\n\n3.2\n\n[Certificate of Amendment to Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1339970/000156459019024064/life-ex31_7.htm)\n\n8-K\n\n001-37378\n\n3.1\n\nJune 28, 2019\n\n3.3\n\n[Certificate of Amendment to Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1339970/000156459020024729/life-ex33_130.htm)\n\n10-Q\n\n001-37378\n\n3.3\n\nMay 12, 2020\n\n3.4\n\n[Certificate of Amendment to Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1339970/000156459021023319/life-ex31_14.htm)\n\n8-K\n\n001-37378\n\n3.1\n\nMay 4, 2021\n\n3.5\n\n[Certificate of Amendment to Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1339970/000156459022016548/life-ex31_8.htm)\n\n8-K\n\n001-37378\n\n3.1\n\nApril 29, 2022\n\n3.6\n\n[Certificate of Amendment to Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1339970/000095017023023257/life-ex3_1.htm)\n\n \n\n8-K\n\n001-37378\n\n3.1\n\nMay 19, 2023\n\n3.7\n\n[Certificate of Amendment to Restated Certificate of Incorporation of the Registrant](atyr-ex3_7.htm)\n\n—\n\n—\n\n—\n\nFiled herewith\n\n3.8\n\n[Amended and Restated Bylaws of the Registrant](https://www.sec.gov/Archives/edgar/data/1339970/000095017022024724/life-ex3_6.htm)\n\n10-Q\n\n333-203272\n\n3.6\n\nNovember 14, 2022\n\n4.1\n\n[Specimen Common Stock Certificate](https://www.sec.gov/Archives/edgar/data/1339970/000119312515148013/d819057dex41.htm)\n\nS-1/A\n\n333-203272\n\n4.1\n\nApril 27, 2015\n\n10.1\n\n[aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended](atyr-ex10_1.htm)\n\n—\n\n—\n\n—\n\nFiled herewith\n\n31.1\n\n[Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](atyr-ex31_1.htm)\n\n—\n\n—\n\n—\n\nFiled herewith\n\n31.2\n\n[Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](atyr-ex31_2.htm)\n\n—\n\n—\n\n—\n\nFiled herewith\n\n32.1#\n\n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](atyr-ex32_1.htm)\n\n—\n\n—\n\n—\n\nFurnished herewith\n\n32.2#\n\n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](atyr-ex32_2.htm)\n\n—\n\n—\n\n—\n\nFurnished herewith\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document\n\n—\n\n—\n\n—\n\nFiled herewith\n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema with Embedded Linkbase Document\n\n—\n\n—\n\n—\n\nFiled herewith\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n—\n\n—\n\n—\n\nFiled herewith\n\n \n\n66\n\n \n\n# The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.\n\n \n\n67\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\naTyr Pharma, Inc.\n\n \n\n \n\n \n\n \n\nDate: May 15, 2026\n\nBy:\n\n \n\n/s/ Sanjay S. Shukla\n\n \n\n \n\n \n\nSanjay S. Shukla, M.D., M.S.\n\n \n\n \n\nPresident, Chief Executive Officer and Director\n\n \n\n \n\n \n\n (Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n \n\n/s/ Jill M. Broadfoot\n\n \n\n \n\nJill M. Broadfoot\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n68"}